Condition: Multiple Myeloma · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| UCSF Fresno | Clovis, California, United States | Active Not Recruiting |
| UCLA | Santa Monica, California, United States | Active Not Recruiting |
| Yale University School Of Medicine | New Haven, Connecticut, United States | Active Not Recruiting |
| Medical Oncology Hematology Consultants, PA | Newark, Delaware, United States | Recruiting |
| Memorial Healthcare System | Hollywood, Florida, United States | Active Not Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Active Not Recruiting |
| Winship Cancer Institute Emory University | Atlanta, Georgia, United States | Active Not Recruiting |
| City of Hope Cancer Center | Newnan, Georgia, United States | Recruiting |
| Kootenai Health | Coeur d'Alene, Idaho, United States | Completed |
| Loyola University Medical Center | Maywood, Illinois, United States | Active Not Recruiting |
| University of Iowa Health Care | Waukee, Iowa, United States | Active Not Recruiting |
| Norton Cancer Institute | Louisville, Kentucky, United States | Active Not Recruiting |
+ 230 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06208150